A bridging stent to surgery in patients with esophageal and gastroesophageal junction cancer has a dramatic negative impact on patient survival

• DOI: 10.1111/dote.12474
• Publication Date: 2016-03-22T12:14:23Z
• Authors: D. W. Kjaer; M. Nassar; L. S. Jensen; L. B. Svendsen; F. V. Mortensen
• Keywords: Esophageal stent

This study aimed to assess the impact of esophageal stenting on postoperative complications and survival in patients with obstructing gastroesophageal junction (GEJ) cancer. All treated without neoadjuvant therapy that had an R0-resection performed for GEJ cancer between January 2003 December 2010 were identified from a prospectively maintained database. Data stenting, mortality, morbidity, recurrence-free survival, complications, length hospital stay collected. Kaplan-Meier plots curves constructed R0 resected patients. compared stent no-stent group by nonparametric tests. Two hundred seventy three consecutive or identified. Of these patients, 63 as bridge surgery. The male/female ratio was 2.64 (198/75) median age (SG) 65.1 versus 64.3 no (NSG). Patients comparable respect gender, age, smoking, TNM-classification, oncological treatment, stay, tumor location, histology. SG 11.6 months 21.3 bridging (P < 0.001). There statistically significant differences 30-day mortality two groups, but NSG exhibited significantly better two-year = 0.017). 9.1 15.2 NSG. use procedure surgery neaoadjuvant later underwent resection decreased year survival.